MX2022006846A - Conjugados y metodos para tratar la fibrosis hepatica. - Google Patents

Conjugados y metodos para tratar la fibrosis hepatica.

Info

Publication number
MX2022006846A
MX2022006846A MX2022006846A MX2022006846A MX2022006846A MX 2022006846 A MX2022006846 A MX 2022006846A MX 2022006846 A MX2022006846 A MX 2022006846A MX 2022006846 A MX2022006846 A MX 2022006846A MX 2022006846 A MX2022006846 A MX 2022006846A
Authority
MX
Mexico
Prior art keywords
conjugates
liver fibrosis
methods
treating liver
double stranded
Prior art date
Application number
MX2022006846A
Other languages
English (en)
Spanish (es)
Inventor
Margrit Schwarz
Xin Ye
Mark Wood
Alan D Martin
James Heyes
Christine Esau
Richard J Holland
Alice Hoy Lam Li
Christopher Justin Pasetka
David Crowe
Steven Tyler
Original Assignee
Genevant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevant Sciences Gmbh filed Critical Genevant Sciences Gmbh
Publication of MX2022006846A publication Critical patent/MX2022006846A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01051—3 (or 17)-Beta-hydroxysteroid dehydrogenase (1.1.1.51)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022006846A 2019-12-06 2020-12-07 Conjugados y metodos para tratar la fibrosis hepatica. MX2022006846A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944963P 2019-12-06 2019-12-06
PCT/US2020/063617 WO2021113820A1 (en) 2019-12-06 2020-12-07 Conjugates and methods for treating liver fibrosis

Publications (1)

Publication Number Publication Date
MX2022006846A true MX2022006846A (es) 2022-10-21

Family

ID=76222671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006846A MX2022006846A (es) 2019-12-06 2020-12-07 Conjugados y metodos para tratar la fibrosis hepatica.

Country Status (11)

Country Link
US (1) US20220387600A1 (cg-RX-API-DMAC10.html)
EP (1) EP4069276A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023505434A (cg-RX-API-DMAC10.html)
KR (1) KR20220112788A (cg-RX-API-DMAC10.html)
CN (1) CN115884984A (cg-RX-API-DMAC10.html)
AU (1) AU2020398708A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022010613A2 (cg-RX-API-DMAC10.html)
CA (1) CA3163911A1 (cg-RX-API-DMAC10.html)
IL (1) IL293560A (cg-RX-API-DMAC10.html)
MX (1) MX2022006846A (cg-RX-API-DMAC10.html)
WO (1) WO2021113820A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI859114B (zh) * 2016-04-11 2024-10-21 加拿大商艾爾布圖斯生技公司 靶向組合物
CA3230382A1 (en) * 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
US20230227480A1 (en) * 2021-10-05 2023-07-20 Sanegene Bio Usa Inc. Polyhydroxylated cyclopentane derivatives and methods of use
WO2024175062A1 (zh) * 2023-02-23 2024-08-29 大睿生物医药科技(上海)有限公司 调控KHK基因活性的dsRNA分子
US20240352464A1 (en) * 2023-03-07 2024-10-24 Aligos Therapeutics, Inc. Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
CN119219716A (zh) * 2023-06-30 2024-12-31 上海维申医药有限公司 新型GalNAc的靶向递送片段及其制备和应用
WO2025255972A1 (zh) * 2024-06-13 2025-12-18 广州必贝特医药股份有限公司 用于靶向递送寡核苷酸药物的化合物、缀合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI859114B (zh) * 2016-04-11 2024-10-21 加拿大商艾爾布圖斯生技公司 靶向組合物
CA3059426A1 (en) * 2017-04-11 2018-10-18 Arbutus Biopharma Corporation Targeted compositions
WO2019051257A2 (en) * 2017-09-11 2019-03-14 Arbutus Biopharma Corporation METHODS OF TREATING HEPATITIS B TYPE INFECTIONS
MY207352A (en) * 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
CA3118142A1 (en) * 2018-11-02 2020-05-07 Genevant Sciences Gmbh Therapeutic methods

Also Published As

Publication number Publication date
CN115884984A (zh) 2023-03-31
BR112022010613A2 (pt) 2022-08-16
EP4069276A1 (en) 2022-10-12
EP4069276A4 (en) 2025-10-08
KR20220112788A (ko) 2022-08-11
JP2023505434A (ja) 2023-02-09
AU2020398708A1 (en) 2022-07-14
IL293560A (en) 2022-08-01
NZ788988A (en) 2026-02-27
CA3163911A1 (en) 2021-06-10
US20220387600A1 (en) 2022-12-08
WO2021113820A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
PH12019502333A1 (en) Targeted compositions
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2019015047A (es) Nucleasas guiadas por acidos nucleicos.
CL2022003788A1 (es) Moléculas de unión contra bcma y usos de las mismas
ZA201806861B (en) Targeted nucleic acid conjugate compositions
MX392977B (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
MY195386A (en) Aav Treatment Of Huntington's Disease
MX2018016393A (es) Conjugados para la edición de la superficie de la celula diana.
MX2020008103A (es) Metodos y composiciones para polarizacion de macrofagos.
JOP20210142A1 (ar) تركيبات rnai لتثبيط التعبير الوراثي عن pnpla3 وطرق استخدامها
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
EA202191210A1 (ru) Способы лечения
EA201691384A3 (ru) Конструкции варианта sirp-альфа и их применение
MX2017011298A (es) Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53.
BR112018072716A2 (pt) molécula de ácido nucleico, composição, e, métodos para tratar uma doença e para prevenir ou tratar a formação de um biofilme.
BR112022010613A2 (pt) Composto da fórmula, métodos de tratamento de fibrose hepática, de tratamento de esteatose hepática não alcoólica e de tratamento de esteatose hepática alcoólica, usos, método ou uso, molécula de sirna, composição e invenção
EA202091520A1 (ru) Композиции на основе irna против бокса-1 высокомобильной группы (hmgb1) и способы их применения
WO2021081420A3 (en) Conjugates and methods for treating acromegaly
CA3241897A1 (en) Crosslinking antibodies
EA201992411A1 (ru) Направленные композиции
EA202190819A1 (ru) Способы направленной вставки днк в гены
AR111637A1 (es) Composiciones dirigidas
EA201892299A1 (ru) Композиции конъюгата направленной нуклеиновой кислоты
AR115451A1 (es) Moléculas de unión contra bcma y usos de las mismas
EA201991181A1 (ru) Psma-нацеленные триспецифические белки и способы их применения